Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Wnt/β-catenin pathway in ovarian cancer: a review.
Arend RC, Londoño-Joshi AI, Straughn JM Jr, Buchsbaum DJ. Arend RC, et al. Gynecol Oncol. 2013 Dec;131(3):772-9. doi: 10.1016/j.ygyno.2013.09.034. Epub 2013 Oct 11. Gynecol Oncol. 2013. PMID: 24125749 Review.
A Review of the Role of Wnt in Cancer Immunomodulation.
Goldsberry WN, Londoño A, Randall TD, Norian LA, Arend RC. Goldsberry WN, et al. Among authors: arend rc. Cancers (Basel). 2019 Jun 4;11(6):771. doi: 10.3390/cancers11060771. Cancers (Basel). 2019. PMID: 31167446 Free PMC article. Review.
Neutrophilia and mortality in women with uterine carcinosarcoma.
Arend R, Van Arsdale A, Gojayev A, Roane BM, Doo D, Leath C, Goldberg GL, Huang G. Arend R, et al. Int J Gynecol Cancer. 2019 Oct;29(8):1258-1263. doi: 10.1136/ijgc-2019-000440. Epub 2019 Jul 17. Int J Gynecol Cancer. 2019. PMID: 31320488
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.
Arend RC, Davis AM, Chimiczewski P, O'Malley DM, Provencher D, Vergote I, Ghamande S, Birrer MJ. Arend RC, et al. Gynecol Oncol. 2020 Feb;156(2):301-307. doi: 10.1016/j.ygyno.2019.12.002. Epub 2019 Dec 20. Gynecol Oncol. 2020. PMID: 31870556 Clinical Trial.
Biomarkers in ovarian cancer: To be or not to be.
Arend R, Martinez A, Szul T, Birrer MJ. Arend R, et al. Cancer. 2019 Dec 15;125 Suppl 24:4563-4572. doi: 10.1002/cncr.32595. Cancer. 2019. PMID: 31967683 Free article. Review.
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.
Arend RC, Beer HM, Cohen YC, Berlin S, Birrer MJ, Campos SM, Rachmilewitz Minei T, Harats D, Wall JA, Foxall ME, Penson RT. Arend RC, et al. Gynecol Oncol. 2020 Jun;157(3):578-584. doi: 10.1016/j.ygyno.2020.02.034. Epub 2020 Apr 5. Gynecol Oncol. 2020. PMID: 32265057 Free article. Clinical Trial.
107 results